單株伽瑪球蛋白症與Ph陰性骨髓增生性腫瘤患者之關連

10.6666/ClinMed.201909_84(3).0100

周以新；劉耀中

骨髓增生性腫瘤（myeloproliferative neoplasm, MPN） ； 意義不明單株伽瑪球蛋白症（monoclonal gammopathy of undetermined significance, MGUS） ； 介白素-6（IL-6）

臨床醫學月刊

84卷3期（2019 / 09 / 27）

606 - 612

繁體中文

許多病例報告曾指出在患有費城染色體陰性骨髓增生性腫瘤的患者會出現意義不明單株伽瑪球蛋白症或多發性骨髓瘤，但僅有少數相關的世代研究被發表。近年來，有研究指出新診斷為真性紅細胞增多症或原發性血小板增多症的患者，如果發現同時具有M-protein，則整體存活期明顯低於無M-protein的患者；透過單變量分析鑑定出M-protein的出現是骨髓纖維化（p=0.02）、骨髓分化不良症候群（p=0.043）及續發性多發性骨髓瘤／華氏巨球蛋白血症（p＜0.0001）的潛在危險因素。因此，本研究旨在探討M-protein的檢測得以協助鑑定出上述類型之患者的可能性。

1. Cesana, C,Klersy, C,Barbarano, L(2002).Prognostic factors for malignant transform tion in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.J Clin Oncol,20,1625-1634.
2. Clech, Lenaïg Le(2017).The presenceof monoclonal gammopathy in Phnegative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.Leukemia & Lymphoma,58,2582-2587.
3. Delhommeau, F,Dupont, S,Tonetti, C(2007).Evidence that the JAK2 G1849T(V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathicmyelofibrosis.Blood,109,71-77.
4. Eskazan, AE,Ongoren, S,Ar, MC(2011).Essential thrombocythemia and multiple myeloma: two rare diseases in onepatient.Clin Lymphoma Myeloma Leuk,11,442-445.
5. Hawley, RG(1995).Interleukin-6-type cytokines in myeloproliferative disease.Ann N Y Acad Sci,762,294-307.
6. Katzmann, JA,Clark, R,Kyle, RA(2013).Suppression of uninvolved immunoglobulins def ned by heavy/light chain pair suppression is a risk factor for progression of MGUS.Leukemia,27,208-212.
7. Kyle, RA,Therneau, TM,Rajkumar, SV(2002).A long-term study of prognosisi n monoclonal gammopathy of undetermined signifi cance.N Engl J Med,346,564-569.
8. Kyle, RA,Therneau, TM,Rajkumar, SV(2006).Prevalence of monoclonal gammopathy of undetermined signifi cance.N Engl J Med,354,1362-1369.
9. Landgren, O,Kyle, RA,Pfeiffer, RM(2009).Monoclonal gammopathy ofundetermined signifi cance(MGUS) consistently precedes multiple myeloma: a prospective study.Blood,113,5412-5417.
10. Majhail, NS,Lichtin, AE(2003).Rare coexistence of multiple myeloma with essential thrombocythemia: report of two cases.Haematologica,88,ECR09.
11. Malhotra, J,Kremyanskaya, M,Schorr, E(2014).Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.Clin Lymphoma Myeloma Leuk,14,31-36.
12. Orlowski, RZ,Gercheva, L,Williams, C(2015).A phase 2, randomized, doubleblind, placebo-controlled study of siltuximab(anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.Am J Hematol,90,42-44.
13. Palumbo, A,Anderson, K(2011).Multiple myeloma.N Engl J Med,364,1046-1060.
14. Pérez-Persona, E,Vidriales, MB,Mateo, G(2007).New criteria to identify risk of progression in monoclonal gammopathy funcertain significance and smoldering multiple myeloma based on multiparameter fl ow cytometry analysis of bone marrow plasma cells.Blood,110,2586-2592.
15. Quintas-Cardama, A,Vaddi, K,Liu, P(2010).Preclinical characterization of theselective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.Blood,115,3109-3117.
16. Rajkumar, SV(2011).Treatment of multiple myeloma.Nat Rev Clin Oncol,8,479-491.
17. Rajkumar, SV,Dispenzieri, A,Kyle, RA(2006).Monoclonal gammopathy of undetermined signifi cance, Waldenstrom macroglobulinemia, AL amyloidosis,and related plasma cell disorders: diagnosis and treatment.Mayo Clin Proc,81,693-703.
18. Rajkumar, SV,Kyle, RA,Therneau, TM(2005).Serum free light chain ratio is an independent risk factor forprogression in monoclonal gammopathy of undetermined signifi cance.Blood,106,812-817.
19. Rosean, TR,Tompkins, VS,Tricot, G(2014).Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.Immunol Res,59,188-202.
20. Turesson, I,Kovalchik, SA,Pfeiffer, RM(2014).Monoclonal gammopathy of undetermined signifi cance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.Blood,123,338-345.
21. Weiss, BM,Abadie, J,Verma, P,Howard, RS,Kuehl, WM(2009).A monoclonal gammopathy precedes multiple myeloma in most patients.Blood,113,5418-5422.